A nurse is caring for a client who has cirrhosis of the liver and is receiving spironolactone. Which of the following findings indicates that the client is responding to the treatment?

A) Elevate the extremity: This action helps reduce swelling and minimizes the spread of infiltrated fluid into surrounding tissues by using gravity to assist in draining the excess fluid back into the bloodstream. Elevating the affected limb above the level of the heart promotes venous return and can help prevent further tissue damage.

B) Flush the IV catheter: Flushing the IV catheter could exacerbate infiltration by pushing more fluid into the surrounding tissue. It is not the appropriate action for managing infiltration and could worsen the client's condition.

C) Slow the infusion rate: Slowing the infusion rate is a reasonable action to reduce the flow of fluid into the tissues and minimize further infiltration. However, it may not be sufficient to manage existing infiltration effectively or prevent tissue damage.

D) Apply pressure to the IV site: Applying pressure to the IV site is not recommended for managing infiltration. It could cause further tissue damage and discomfort for the client and is not considered a standard practice in managing this complication.

A) Digoxin and levothyroxine: Digoxin is a cardiac glycoside used to treat heart failure and atrial fibrillation, while levothyroxine is a thyroid hormone replacement medication used to treat hypothyroidism. While both medications have potential side effects, hearing loss is not typically associated with either digoxin or levothyroxine. Therefore, monitoring for hearing loss related to a medication interaction is not a priority for clients taking digoxin and levothyroxine.

B) Losartan and atorvastatin: Losartan is an angiotensin II receptor blocker used to treat hypertension, while atorvastatin is a statin medication used to lower cholesterol levels. Hearing loss is not a known side effect of either losartan or atorvastatin, nor is there evidence of an interaction between these medications that would increase the risk of hearing loss. Therefore, monitoring for hearing loss related to a medication interaction is not indicated for clients taking losartan and atorvastatin.

C) Propranolol and raloxifene: Propranolol is a beta-blocker used to treat hypertension, angina, and other cardiovascular conditions, while raloxifene is a selective estrogen receptor modulator used to prevent and treat osteoporosis in postmenopausal women. Neither propranolol nor raloxifene is associated with hearing loss as a common side effect. Additionally, there is no known interaction between propranolol and raloxifene that would increase the risk of hearing loss. Therefore, monitoring for hearing loss related to a medication interaction is not necessary for clients taking propranolol and raloxifene.

D) Furosemide and amikacin: Furosemide is a loop diuretic that is commonly used to treat fluid overload conditions such as heart failure and edema. Amikacin is an aminoglycoside antibiotic used to treat bacterial infections. Both furosemide and amikacin have the potential to cause ototoxicity, which can manifest as hearing loss or tinnitus. When administered concurrently, especially at higher doses or for prolonged durations, the risk of ototoxicity may increase due to additive or synergistic effects on the inner ear structures. Therefore, the nurse should monitor clients receiving both furosemide and amikacin for signs of hearing loss, such as changes in hearing acuity or tinnitus, and promptly report any concerns to the healthcare provider for further evaluation and management.